MAYZENT® (siponimod) tablets , for oral use Siponimod is a sphingosine-1-phosphate (S1P) receptor modulator. Siponimod binds with high affinity to S1P receptors 1 and 5. Siponimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which siponimod exerts therapeutic effects in multiple sclerosis is unknown but may involve the reduction of lymphocyte migration into the central nervous system. Initial U.S. Approval: 2019 INDICATIONS AND USAGE MAYZENT is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. DOSAGE AND ADMINISTRATION Assessments are required prior to initiating MAYZENT Titration is required for treatment initiation The recommended maintenance dosage is 2 mg The recommended maintena...